Skip to Content

Novo Nordisk A/S ADR NVO

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Maintaining Our $73/DKK 453 FVE for Novo Nordisk Following Emerging Strength in Q1

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

Novo Nordisk reported first-quarter results that were slightly above our expectations, with 7% top-line growth at constant currencies (flat as reported, due to currency headwinds). This performance is particularly strong, given the pandemic-related stocking that boosted sales in the year-ago quarter; after adjusting for stocking and shipment timing, underlying first-quarter sales growth was closer to 9% at constant currencies. We have raised our forecast for 2021 reported sales growth from 5% to 6.6%, putting it at the higher end of management's new 2%-6% reported sales growth guidance (6%-10% at constant currencies). However, after slightly tempering our U.S. GLP-1 growth estimates for the year, and factoring in upcoming potential pressure on China sales of insulin from volume-based procurement, this doesn't significantly change our valuation, and we're maintaining our fair value estimate of $73/DKK 453 per share. We see U.S. growth slightly improving in 2021 as Novo annualizes some step-ups in affordability initiatives from 2020 for its insulin therapies and as the Rybelsus launch should accelerate. While Novo is increasingly reliant on semaglutide for growth opportunities, diversification among indications and formulations to protect the franchise, in our view, and we think the firm's continued innovation in cardiometabolic-related disorders warrants a wide moat.

Read Full Analysis

Company Profile

Business Description

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Alle 1
Bagsvaerd, DK-2880, Denmark
T +45 44448888
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2021
Stock Type
Employees 45,777